Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.
Transcription:
To our surprise, we found that the progression-free survival going forward was better if you stayed on (lenalidomide) maintenance. So, at 6 years, 79.5 maybe 80% of patients who were on (lenalidomide) continued to remain progression-free and alive. On the other arm, the people who stopped (lenalidomide), only 61%, so there’s a pretty dramatic drop off in the number of patients who progressed when they stopped (lenalidomide). This actually leads us to the conclusion that we have not been able to identify a point at which it is completely safe to stop (lenalidomide) maintenance even if you are progression-free at 3 years.
I…
